TABLE 5.

Clinical trials of regulatory agents targeting cGAS-STING pathways.

Control agents	Control targets	Clinical trials	Disease
Aspirin	h-cGAS	Not applicable (NCT04132791) (NCT03603366) a total of 2,269 studies	Cardiovascular disease, cancer of the colon and rectum
Suramin	h-cGAS	Phase 1/2 (NCT00054028) a total of 21 studies	Stage IIIB-IV breast cancer
CXA-10	h-STING	Phase 2 (NCT03422510) a total of 11 studies	FSGS
ADU-S100	h-STING	Phase 2 (NCT03937141) phase 1 (NCT02675439) phase 1 (NCT03172936)	Head and neck cancer, advanced/metastatic solid tumors or lymphomas
MK-1454	h-STING	Phase 2 (NCT04220866) phase 1 (NCT03010176)	Neck squamous cell carcinoma, advanced/metastatic solid tumor, or lymphoma
BMS-986301	h-STING	Phase 1 (NCT03956680)	Advanced solid tumor
DMXAA (ASA404)	m-STING	Phase 1 (NCT00863733) phase 1 (NCT00856336) phase 1/2 (NCT00832494) a total of 18 studies	Solid tumors, DART, advanced non-small cell lung cancer
Tucatinib	HER2	Phase 1/2 (NCT03054363) phase 2 (NCT04579380) phase 2 (NCT03043313) phase 1/2 (NCT04430738) a total of 34 studies	Breast cancer, solid tumors, HER2+ colorectal cancer, HER2+ gastrointestinal cancers
EGCG	G3BP1	Phase 2 (NCT04553666) phase 0 (NCT02891538) phase 1 (NCT04177693) a total of 117 studies	Older cancer, colorectal cancer, pharmacokinetics, and hepatic safety